We cover the US equity market. View live ABCELLERA BIOLOGICS INC chart to track its stock's price action. AbCellera Biologics is now listed on the Nasdaq under "ABCL." What it is building however is known all throughout the biotech and pharma industries. ABCL stock trade performance evaluation. The initial public offering (IPO) has long been the primary vehicle for companies entering the public markets. Chart Pine Script Stock Screener Forex Screener Crypto Screener Economic Calendar Earnings Calendar. Airbnb, AbCellera, Snowflake… these are all recently public companies. The Average True Range (ATR) for AbCellera Biologics Inc. is set at 7.59, with the Price to Sales ratio for ABCL stock in the period of the last 12 months amounting to 556.06. The company has offered to sell 24.15 million shares of its common stock at a price of $20 each. Predictions of ABCL stock price for tomorrow. Check if ABCL has a Buy or Sell Evaluation. Get the latest AbCellera Biologics Inc. ABCL detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. We use big data and artificial intelligence to forecast the stock price of AbCellera Biologics Inc Ordinary Shares - ABCL. In the medium term (3months), NARI's stock price should underperform the market by -3.87%. Get the hottest stocks to trade every day before the market opens 100% free. A shining light of Vancouver's tech industry is now trading on one of North America's premier stock exchanges. AbCellera had initially sought to sell 23 million shares at US$14 to US$17 apiece, but later boosted the price range to US$17 to US$18 before ultimately offering 24.2 million shares at US$20 each. It has also generated negative returns for investors over the last 30 days. Our stock price predictions cover a period of 3 months. 2. The prediction is based on 5 analyst estimates. AbCellera will present at the 10th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 1:20 p.m. Pacific Time. Enbridge finally hit a 52-week low this week, and even Fortis was grinding at a year-long low. The stock market is crashing, and energy stocks are in turmoil. The AbCellera IPO filing also provides a price range of $14 to $17 per share for its stock. AbCellera Biologics is a little followed and largely uncovered company. And this is happening everywhere. But when it started trading, the stock immediately jumped above $100. AbCellera's stock opened Friday at $61. The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. Find market predictions, ABCL financials and market news. Return on Equity for this stock declined to -20.22, with Return on Assets sitting at -9.83. View today's stock price, news and analysis for AbCellera Biologics Inc. (ABCL). AbCellera Biologics currently has 5 buy ratings from Wall Street analysts. Image source: Getty Images . Measured by dollars raised, AbCellera's is the second-biggest public offering of any biotech this year, and the fourth largest since the start of 2018, trailing only Moderna, Royalty Pharma and Genmab. A stock is considered to be oversold if the RSI reading falls below 30. We are all together in this COVID-19 pandemic. AbCellera Biologics Inc. Common Shares (ABCL) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. AbCellera… AbCellera Biologics picks internal candidate for CTO: Feb 11: AbCellera Appoints Ester Falconer, Ph.D., as Chief Technology Officer: Feb 10: IPO Stock AbCellera Nears Breakout After Lilly-Partnered Covid Drug Nabs OK: Feb 10: AbCellera shares jump after bamlanivimab combo nabs FDA's EUA for COVID-19 treatment: Feb 10 Investors never had a chance to invest at a reasonable valuation. The stock has a consensus analyst rating of "Buy." This is a 0.62 percent up since the beginning of the trading day. Abcellera Biologics Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. NARI stock forecast Our latest prediction for Inari Medical Inc's stock price was made on the Feb. 10, 2021 when the stock price was at 112.55$.. AbCellera Biologics Inc. (NASDAQ:ABCL) shares, dropped in value on Friday, Feb 26, with the stock price down by -3.46% to the previous day’s close as weak demand from buyers trailed the stock to $37.71. What is ABCL stock forecast (i.e., prediction)? Updated world stock indexes. Abcellera Biologics is selling for 44.07 as of the 22nd of February 2021. In the short term (2weeks), NARI's stock price should underperform the market by -1.70%.During that period the price should oscillate between -9.05% and +7.75%.. Based on ABCL analyst price targets, ABCL stock forecast is $55.80 (for a year from now). AbCellera announced the pricing of its initial public offering of 24,150,000 common shares at a price to the public of $20.00 per share. How to buy shares in AbCellera Biologics AbCellera Biologics CEO Carl Hansen joins 'Closing Bell' to discuss the company's partnership with Eli Lilly in developing monoclonal antibody treatment and the company's Covid-19 treatments. Credit Suisse, Stifel, Berenberg, SVG Leerink and BMO Capital Markets were the underwriters. View AbCellera Biologics Inc. ABCL investment & stock information. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Analyst Predictions. ABCL Stock Price (NASDAQ), Score, Forecast, Predictions, and AbCellera Biologics Inc. News. Price trends tend to persist, so it's worth looking at them when it comes to a share like Abcellera Biologics Inc. Over the past six months, the relative strength of its shares against the market has been %. AbCellera further elevates a historic time for biotech IPOs. Check out the latest ideas and forecasts on ABCELLERA BIOLOGICS INC from our top authors — they share predictions and technical outlook of the market. The stock was priced at around $42. A high-level overview of AbCellera Biologics Inc. (ABCL) stock. The stock's lowest day price was 43.56.Abcellera Biologics has a very high chance of experiencing financial distress in the next few years of operation. A "buy" rating indicates that analysts believe ABCL will outperform the market and that investors should add to their positions of AbCellera Biologics. Return on Total Capital for ABCL is now -26.23, given the latest momentum, and Return on Invested Capital for the company is -16.51. AbCellera has a portfolio with hundreds of programs and posted net income of US$1.9 million on revenue of US$25 million in the nine months ended Sept. 30, according to its IPO filing. The company plans to offer 23 million shares in the IPO. AbCellera originally set its price range at between $14 and $17 per share. An important predictor of whether a stock price will go up is its track record of momentum. AbCellera Biologics Inc Stock Price Forecast, "ABCL" Predictons for2021 The big decline in price over the last few months for Abcellera Biologics could raise concerns from stakeholders as the firm it trading at a share price of 40.10 on 660,402 in volume. Almost every stock on the market today was an IPO stock at one point in its history. AbCellera Biologics Inc.’s Net Margin is presently recorded at -19.04. Your losses are our losses too. Click here now. View the latest ratings for ABCL. Get an overview of major world indexes, current values and stock market data. That means the average analyst price target for ABCL stock is $55.80.